Mode of action of aspirin as a chemopreventive agent

Recent Results in Cancer Research

Volumn 191, Issue , 2013, Pages 39-65

  Dovizio, Melania ^a   Bruno, Annalisa ^a   Tacconelli, Stefania ^a   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOENZYME;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL NUCLEUS; COLORECTAL CANCER; CYCLOOXYGENASE 2 GENE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIUM INJURY; ENZYME INHIBITION; EPITHELIAL INJURY; EXOSOME; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HUMAN; LOW DRUG DOSE; MEDIATOR RELEASE; METASTASIS; NONHUMAN; NUCLEATED CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS; TISSUE INJURY; WNT SIGNALING PATHWAY;

EID: 84867063821     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-30331-9_3     Document Type: Article

References (119)

1. Alfonso LF, Srivenugopal KS, Arumugam TV et al (2009a) Aspirin inhibits camptothecin-induced p21CI P1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol 34:597-608
2. Alfonso LF, Srivenugopal KS, Bhat GJ (2009b) Does aspirin acetylate multiple cellular proteins? Mol Med Report 2:533-537
3. Archer SY, Hodint RA (1999) Histone acetylation and cancer. Curr Opin Genet Dev 9:171-174
4. Baigent C and Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324:71-86
5. Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899
6. Bastida E, Escolar G, Ordinas A et al (1986) Morphometric evaluation of thrombogenesis by microvesicles from human tumor cell lines with thrombin-dependent (U87MG) and adenosine diphosphate-dependent (SKNMC) platelet-activating mechanisms. J Lab ClinMed 108:622-627
7. Benamouzig R, Deyra J, Martin A et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 125:328-336
8. Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884
9. Bos CL, Kodach LL, van den Brink GR et al (2006) Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25:6447-6456
10. Bours V, Bentires-Alj M, Hellin AC et al (2000) Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 60:1085-1089
11. Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 90:279-286
12. Capone ML, Tacconelli S, Di Francesco L et al (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82:85-94
13. Capone ML, Tacconelli S, Sciulli MG et al (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468-1471
14. Cervi D, Yip TT, Bhattacharya N et al (2008) Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111:1201-1207
15. Cha YI, DuBois RN (2007) NSAIDs and cancer prevention: Targets downstream of COX-2. Annu Rev Med 58:239-252
16. Charman WN, Charman SA, Monkhouse DC et al (1993) Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. Br J Clin Pharmac 36:470-473
17. Chen Z, Hagler J, Palombella VJ et al (1995) Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9:1586-1597
18. Chulada PC, Thompson MB, Mahler JF et al (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705-4708
19. Cipollone F, Patrignani P, Greco A et al (1997)Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96:1109-1116
20. Clarke RJ, Mayo G, Price P et al (1991) Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137-1141
21. Collier JC, Flower RJ (1971) Effect of Aspirin on human seminal prostaglandins. Lancet ii:852-853
22. Creagh EM, Conroy H, Martin SJ (2003) Caspase-activation pathways in apoptosis and immunity. Immunol Rev 193:10-21
23. Cuzick J, Otto F, Baron JA et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol 10:501-507
24. Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
25. Delattre O, Olschwang S, Law DJ et al (1989) Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2:353-356
26. Di Francesco L, Totani L, Dovizio M et al (2009) Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res 104:506-513
27. Dixon DA, Tolley ND, Bemis-Standoli K et al (2006) Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 116:2727-2738
28. Dixon DA, Tolley ND, King PH et al (2001) Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2108:1657-1665
29. Donnini S, Finetti F, Solito R et al (2007) EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J 21:2418-2430
30. Dovizio M, Tacconelli S, Ricciotti E et al (2012) Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. J Pharmacol Exp Ther 341:242-250
31. Dreser H (1899) Pharmakologisches über aspirin (acetylsalicylsä ure). Pfluger's Arch 76:306-318
32. EvangelistaV,ManariniS,DiSantoAet al (2006)De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 98:593-595
33. Ferreira SH, Moncada S, Vane JR (1971) Indomethacin and Aspirin abolish prostaglandin release from spleen. Nature 231:237-239
34. Fierro IM, Kutok JL, Serhan CN (2002) Novel lipid mediator regulators of endothelial cell proliferation and migration: Aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 300:385-392
35. FitzGerald GA (2003) COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2:879-890
36. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ (2001) Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 52:563-571
37. García Rodríguez LA, Lin KJ, Hernández-Díaz S et al (2011) Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011(123):1108-1115
38. Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123-134
39. Geest CR, Coffer PJ (2009) MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 86:237-250
40. Gilroy DW (2005) The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukot Essent Fatty Acids 73:203-210
41. Grilli M, Pizzi M, Memo M et al (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kB activation. Science 274:1383-1385
42. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116:4-15
43. Gu Q, Wang JD, Xia HH et al (2005) Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis 26:541-546
44. Hanif R, Pittas A, Feng Y et al (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandinindependent pathway. Biochem Pharmacol 52:237-245
45. Harper KA, Tyson-Capper AJ (2008) Complexity of COX-2 gene regulation. Biochem Soc Trans 36:543-545
46. Hemler M, Lands WEM, Smith WL (1976) Purification of the cyclooxygenase that forms prostaglandins: Demonstrationof two forms of iron in the holoenzyme. JBiolChem251:5575-5579
47. Honn K (1983) Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis 1:103-114
48. Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101:403-408
49. Italiano JE Jr, Richardson JL, Patel-Hett S et al (2008) Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111:1227-1233
50. Jana NR (2008) NSAIDs and apoptosis. Cell Mol Life Sci 65:1295-1301
51. Janowska-Wieczorek A, Wysoczynski M, Kijowski J et al (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113:752-760
52. Jurasz P, Alonso-Escolano D, Radomski MW (2004) Platelet - cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143:819-826
53. Kang YJ, Mbonye UR, DeLong CJ et al (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 46:108-125
54. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956-959
55. Kujubu DA, Fletcher BS, Varnum BC (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866-12872
56. Kulmacz RJ, Lands WE (1985) Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 260:12572-12578
57. Kurumbail RG, Stevens AM, Gierse JK et al (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648
58. Lecomte M, Laneuville O, Ji C et al (1994) Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 269:13207-13215
59. Loll PJ, Picot D, Garavito RM (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2:637-643
60. Mann B, Gelos M, Siedow A et al (1999) Target genes of beta-catenin-T cell-factor/lymphoidenhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 96:1603-1608
61. Mause SF, Weber C (2010) Microparticles: Protagonists of a novel communication network for intercellular information exchange. Circ Res 107:1047-1057
62. Meade TW, Framework The Medical Research Council's General Practice Research (1998) Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233-241
63. Menter DG, Onoda JM, Moilanen D et al (1987) Inhibition by prostacyclin of the tumor cellinduced platelet release reaction and platelet aggregation. J Natl Cancer Inst 78:961-969
64. Miller JR, Hocking AM, Brown JD et al (1999) Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 18:7860-7872
65. Minuz P, Fumagalli L, Gaino S et al (2006) Rapid stimulation of tyrosine phosphorylation signals downstream of Gprotein- coupled receptors for thromboxane A2 in human platelets. Biochem J. 400:127-134
66. Needleman P, Moncada S, Bunting S et al (1976) Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261:558-560
67. Nieswandt B, Hafner M, Echtenacher B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295-1300
68. Okajima F (2002) Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: Is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta 1582:132-137
69. Pacienza N, Pozner RG, Bianco GA et al (2008) The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J 22:1113-1123
70. Padua D, Zhang XH, Wang Q et al (2008) TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133:66-77
71. Paganini-Hill A, Chao A, Ross RK et al (1989) Aspirin use and chronic diseases: A cohort study of the elderly. BMJ 299:1247-1250
72. Pan MR, Chang HC, Hung WC (2008) Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal 20:1134-1141
73. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366-1372
74. Patrignani P, Panara MR, Greco A et al (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1705-1712
75. Patrono C, Baigent C, Hirsh J et al (2008) Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines. Chest 133:199S - 233S 8th edn
76. Patrono C, Ciabattoni G, Patrignani P et al (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72:1177-1184
77. Patrono C, Ciabattoni G, Pinca E et al (1980) Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17:317-327
78. Patrono C, García Rodríguez LA, Landolfi R et al (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
79. Patrono C, Patrignani P, García Rodríguez LA (2001) Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7-13
80. Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclo-oxygenase. N Engl J Med 311:1206-1211
81. Picot D, Loll PJ, Garavito RM (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367:243-249
82. Pradono P, Tazawa R, Maemondo M et al (2002) Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62:63-66
83. Prescott SM (2000) Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest 105:1511-1513
84. Pyne NJ (2010) Pyne S (2010) Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10:489-503
85. Rimon G, Sidhu RS, Lauver DA et al (2010) Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci USA 107:28-33
86. Romano M (2006) Lipid mediators: Lipoxin and aspirin-triggered 15-epi-lipoxins. Inflamm Allergy Drug Targets 5:81-90
87. Romano M (2010) Lipoxin and aspirin-triggered lipoxins. Sci World J 10:1048-1064
88. Roth GJ, Majerus PW (1975) The mechanism of the effect of aspirin on human platelets: 1 acetylation of a particulate fraction protein. J Clin Invest 56:624-632
89. Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 72:3073-3076
90. Rothwell PM, Fowkes FG, Belch JF et al (2011) Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 377:31-41
91. Rothwell PM, Wilson M, Elwin CE et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow-up of five randomised trials. Lancet 376:1741-1750
92. Rumble RH, Brooks PM, Roberts MS (1980) Metabolism of salicylate during chronic aspirin therapy. Br J Clin Pharmac 9:41-45
93. Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890
94. Sciulli MG, Filabozzi P, Tacconelli S et al (2005) Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 72:79-83
95. Serhan CN (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73:141-162
96. Seymour RA, Rawlins MD (1982) Efficacy and pharmacokinetics of aspirin in post-operative dental pain. J. Clin. Pharmac. 13:807-810
97. Sharma NP, Dong L, Yuan C et al (2010) Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. Mol Pharmacol 77:979-986
98. Sharma S, Yang SC, Zhu L et al (2005) Tumor cyclooxygenase-2/ prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65:5211-5220
99. Sheehan KM, Sheahan K, O'Donoghue DP et al (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254-1257
100. Sidhu RS, Lee JY, Yuan C et al (2010) Comparison of cyclooxygenase-1 crystal structures: Cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry 49:7069-7079
101. Smith JB, Willis AL (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature 231:235-237
102. Smyth EM, Grosser T, Wang M et al (2009) Prostanoids in health and disease. J Lipid Res 50:S423 - S428
103. Smyth MJH, Dawkins PD (1971) Salicylates and enzyme. J Pharm Pharmacol 23:729-744
104. Stark LA, Din FV, Zwacka RM et al (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15:1273-1275
105. Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952
106. Stone E (1763) An account of the success of the bark of the willow tree in the cure of agues. Philos Trans R Soc Lond. 53:195-200
107. Tani M, Sano T, Ito M et al (2005) Mechanisms of sphingosine and sphingosine 1-phosphate generation in human platelets. J Lipid Res 46:2458-2467
108. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic. Pharmacologic, Clin Issues J Natl Cancer Inst 94:252-266
109. Topper JN, Cai J, Falb D et al (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. PNAS 93:10417-10422
110. Ulrych T, Böhm A, Polzin et al (2011) Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 9:790-798
111. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for Aspirin-like drugs. Nat New Biol 231:232-235
112. Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110:255-258
113. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181-193
114. Weiss HJ, Aledort LM (1967) Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 2:495-497
115. Xie W, Chipman JG, Robertson DL et al (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 88:2692-2696
116. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77-80.
117. Yuan C, Rieke CJ, Rimon G et al (2006) Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci U S A. 103:6142-6147
118. Yuan C, Sidhu RS, KuklevDVet al (2009) Cyclooxygenase Allosterism, FattyAcid-mediated Crosstalk between Monomers of Cyclooxygenase Homodimers. J Biol Chem 284:10046-10055
119. Zimmermann KC, Waterhouse NJ, Goldstein JC et al (2000) Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia 2:505-513